On September 16, Twist Bioscience Corp rose 5.95% in regular trading, trading at approximately $146.05 per share, with turnover of $7.0 million. The stock was driven higher by multiple positive catalysts emerging during the session.

On the news front, the company announced a collaboration with Eli Lilly's TuneLab, an AI/ML drug discovery platform, to provide antibody characterization data services aimed at accelerating antibody drug discovery. Simultaneously, at Baird's Global Healthcare Conference, CEO disclosed that fiscal Q4 revenue is expected to reach approximately $124 million, representing roughly 25% year-over-year growth and marking 15 consecutive quarters of revenue expansion. This figure exceeds the FactSet consensus estimate of $117.4 million. Management also revealed that AI-related pharmaceutical orders have reached $50 million, with expectations to double to $100 million next year.

These developments build on momentum from the company's selection by Anthropic as an independent evaluator for an AI protein design project in August, which drove shares up over 17% in a single session. UBS recently initiated coverage with a Neutral rating and a $144 price target, a level the stock has now surpassed.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)